Jim Simons Praxis Precision Medicines, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $279,444 - $549,252	321,200 Added 48.98%	977,000 $1.67 Million
Q2 2023 Aug 11, 2023	BUY	$0.83 - $1.18 $228,914 - $325,444	275,800 Added 72.58%	655,800 $754,000
Q1 2023 May 12, 2023	BUY	$0.8 - $4.98 $12,800 - $79,680	16,000 Added 4.4%	380,000 $307,000
Q4 2022 Feb 13, 2023	SELL	$1.88 - $36.45 $160,018 - $3.1 Million	-85,116 Reduced 18.95%	364,000 $866,000
Q3 2022 Nov 14, 2022	BUY	$2.5 - $37.95 $579,290 - $8.79 Million	231,716 Added 106.59%	449,116 $1.02 Million
Q2 2022 Aug 12, 2022	BUY	$1.75 - $11.34 $254,800 - $1.65 Million	145,600 Added 202.79%	217,400 $533,000
Q1 2022 May 13, 2022	BUY	$10.21 - $20.29 $599,327 - $1.19 Million	58,700 Added 448.09%	71,800 $733,000
Q4 2021 Feb 11, 2022	BUY	$16.76 - $22.99 $219,556 - $301,169	13,100 New	13,100 $258,000
Q3 2021 Nov 12, 2021	SELL	$13.15 - $22.56 $491,810 - $843,744	-37,400 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.28 - $33.05 $683,672 - $1.24 Million	37,400 New	37,400 $684,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.